ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.768,71
-0,96%
S&P 500
5.956,06
0,01%
US Dollar vs BRL
5,8079
0,05%
Bitcoin
86.123,19
2,44%
Brent Oil
72,685
0,50%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Stoke Therapeutics Inc (STOK)

  7. Stoke Therapeutics Inc (STOK) Notícias

STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:STOK
DataHoraFonteTítuloCódigoCompanhia
26/02/202518:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in MarchNASDAQ:STOKStoke Therapeutics Inc
18/02/202518:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
18/02/202510:00Business WireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
08/01/202518:30Business WireStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
07/01/202509:00Business WireStoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
06/01/202518:30Business WireStoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
27/12/202419:23Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
27/12/202419:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
23/12/202420:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/12/202414:00Business WireStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/12/202409:00Business WireStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
02/12/202410:00Business WireStoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual MeetingNASDAQ:STOKStoke Therapeutics Inc
14/11/202411:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STOKStoke Therapeutics Inc
05/11/202418:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
05/11/202409:00Business WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
09/10/202417:16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:STOKStoke Therapeutics Inc
23/09/202417:22Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
10/09/202408:00Business WireStoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/09/202409:00Business WireStoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business OfficerNASDAQ:STOKStoke Therapeutics Inc
03/09/202409:00Business WireStoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
03/09/202409:00Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in SeptemberNASDAQ:STOKStoke Therapeutics Inc
16/08/202417:30Business WireStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:STOKStoke Therapeutics Inc
07/08/202408:00Business WireStoke Therapeutics Reports Second Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
13/06/202417:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:STOKStoke Therapeutics Inc
03/06/202417:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in JuneNASDAQ:STOKStoke Therapeutics Inc
17/05/202417:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/05/202408:00Business WireStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
29/04/202409:00Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerNASDAQ:STOKStoke Therapeutics Inc
17/04/202409:00Business WireStoke Therapeutics Appoints Jason Hoitt as Chief Commercial OfficerNASDAQ:STOKStoke Therapeutics Inc
04/04/202417:30Business WireStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:STOK

Seu Histórico Recente

EU
SBT
Oeneo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios